Samir Mehta

Medicine & Life Sciences

1. Randomized Controlled Trials 100%
2. Chronic Renal Insufficiency 56%
3. Atrial Fibrillation 54%
4. Chlorthalidone 47%
5. Prednisolone 40%
6. RATE protocol 39%
7. Spironolactone 39%
8. Plasma Exchange 37%
9. Nephrotic Syndrome 34%
10. Steroids 34%
11. Cost-Benefit Analysis 31%
12. Vasculitis 31%
13. Hernia 29%
14. Angiotensin Receptor Antagonists 28%
15. Quality of Life 28%
16. Respiratory Tract Infections 28%
17. Glucocorticoids 28%
18. Bisoprolol 25%
19. Glomerular Filtration Rate 23%
20. Surgeons 22%
21. Angiotensin-Converting Enzyme Inhibitors 22%
22. Placebos 21%
23. Digoxin 21%
24. Chronic Kidney Failure 21%
25. Random Allocation 20%
26. Negative-Pressure Wound Therapy 20%
27. Sudden Hearing Loss 20%
28. Surgical Wound Infection 20%
29. Ulcerative Colitis 20%
30. Postoperative Nausea and Vomiting 19%
31. National Institutes of Health (U.S.) 19%
32. Antineutrophil Cytoplasmic Antibodies 19%
33. Therapeutics 19%
34. Quality-Adjusted Life Years 18%
35. Feasibility Studies 18%
36. Textbooks 18%
37. Esophagectomy 18%
38. Confidence Intervals 17%
39. Dexamethasone 17%
40. Sensorineural Hearing Loss 17%
41. Costs and Cost Analysis 17%
42. Colitis 17%
43. Psychology Reinforcement 16%
44. Bandages 16%
45. Renin-Angiotensin System 15%
46. Incidence 15%
47. Chondrocytes 15%
48. Incisional Hernia 15%
49. Knee 15%
50. Pulmonary Embolism 15%